Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Akebia Therapeutics, Inc. (AKBA) vs Anika Therapeutics Inc. (ANIK)

Akebia Therapeutics, Inc. and Anika Therapeutics Inc. are both Drug Manufacturers Specialty & Generic companies. Akebia Therapeutics, Inc. and Anika Therapeutics Inc. are of similar size ($270.7M and $254.7M). Akebia Therapeutics, Inc. grew revenue faster over the last twelve months: 7.52% against 5.33%. Anika Therapeutics Inc. has the higher net margin (−3.14% vs −13.5%) and the lower return on invested capital (−3.24% vs 0.00%). Across the 19 metrics below, Akebia Therapeutics, Inc. leads on 10 and Anika Therapeutics Inc. on 9.

Valuation

Metric AKBA ANIK Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.11 2.25 2.25
P/B 9.70 1.98 1.90
Price to free cash flow 6.03 483.15 16.54
EV/EBITDA n/m 508.54 12.29
EV/Sales 0.62 2.16 2.56
Earnings yield (12.00%) (1.28%) (2.99%)
Free cash flow yield 16.59% 0.21% 0.00%

Profitability

Metric AKBA ANIK Drug Manufacturers Specialty & Generic median
Gross margin 79.63% 62.16% 53.94%
Operating margin (6.90%) (4.24%) 0.00%
Net margin (13.54%) (3.14%) 0.00%
Free cash flow margin 18.38% 0.47% 0.00%
Return on equity (109.38%) (2.66%) (0.40%)
Return on assets (8.53%) (2.04%) (3.32%)
Return on invested capital 0.00% (3.24%) 0.00%

Growth

Metric AKBA ANIK Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 7.52% 5.33% 10.01%
EPS growth (last fiscal year) 93.94% 80.16% —
Revenue growth, 5-year CAGR (4.33%) (2.86%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AKBA ANIK Drug Manufacturers Specialty & Generic median
Debt to equity 1.98 0.00 0.05
Current ratio 1.43 4.48 2.31
Net debt to EBITDA (5.51) 10.80 0.85

Dividend

Metric AKBA ANIK Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AKBA ANIK Drug Manufacturers Specialty & Generic median
Market cap 254.66m 270.74m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack